AlphaSIP

MAXSAM allows for highly paralyzed testing of biological samples using a combination of in vitro models, robotics and LAMP-based nucleic amplification. This maintains the ultra-compact footprint, a low power requirement, and making the platform ideal for de-centralized mass screenings e.g. in a pandemic situation. This project aims to modular autoanalyzer sample to result that can be self assembled as independently building blocks (like lego toys) to be used as a novel Point-of-Care (POC) diagnostic device, that combines a robotic arm and a microfluidics platform either with a fast PCR (Polymerase chain reaction) microchip and novel detection for the quick diagnosis...

Nano medicine,nano electronics,point of care,covid19,coronavirus,digital pcr,industry 4.0,roll2roll,and flexible electronics

Alphasip operates in the Semiconductor manufacturing industry.

Alphasip's revenue is 11m - 100m

Alphasip has 11 - 50 employees.